- Market Capitalization, $K 122,978,216
- Shares Outstanding, K 2,504,138
- Annual Sales, $ 42,147 M
- Annual Income, $ 3,256 M
- 60-Month Beta 0.60
- Price/Sales 3.05
- Price/Cash Flow 7.33
- Price/Book 1.80
|Period||Period Low||Period High||Performance|
| || |
+0.11 (+0.22%)since 04/29/20
| || |
+2.86 (+6.18%)since 02/28/20
| || |
+8.29 (+20.31%)since 05/29/19
Glaxo (GSK) set to enhance its manufacturing capacity to make 1 billion doses of its pandemic vaccine adjuvant, which can be used to improve efficacy and scale up of multiple COVID-19 vaccines.
Protalix (PLX) announces submission of regulatory application seeking approval for its lead pipeline candidate, pegunigalsidase alfa, for Fabry disease.
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
The biotech sector remains in focus with updates on coronavirus treatments and other pipeline updates.
Alnylam's (ALNY) NDA seeking approval for lumasiran for treating kidney disease, primary hyperoxaluria type 1, gets priority review from the FDA.
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19....
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Regeneron (REGN) commences underwritten public secondary offering of its common stock held by Sanofi and repurchases shares for $5 billion.